Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1045-1051

  Vallee, Audrey ^a   Sagan, Christine ^b   Le Loupp, Anne Gaelle ^a   Bach, Kalyane ^a   Dejoie, Thomas ^a   Denis, Marc G ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Epidermal growth factor receptor mutation; Non small cell lung cancer; TTF 1 expression

Indexed keywords

DNA; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; THYROID TRANSCRIPTION FACTOR 1;

ADENOCARCINOMA; ADULT; ARTICLE; BRONCHUS BIOPSY; CANCER PATIENT; CANCER SURGERY; CAUCASIAN; CLINICAL PRACTICE; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; SCREENING; TRANSBRONCHIAL ASPIRATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84882442762     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2056     Document Type: Article

References (34)

1. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
2. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
3. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
4. Zhou C, Wu Y-L, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
5. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.
6. Querings S, Altmuller J, Ansen S, et al: Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6: e19601, 2011.
7. Marchetti A, Felicioni L and Buttitta F: Assessing EGFR mutations. N Engl J Med 354: 526-528, 2006.
8. Takano T, Ohe Y, Tsuta K, et al: Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 13: 5385-5390, 2007.
9. Do H, Krypuy M, Mitchell P, Fox S and Dobrovic A: High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142, 2008.
10. Fukui T, Ohe Y, Tsuta K, et al: Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 14: 4751-4757, 2008.
11. Didelot A, Le Corre D, Luscan A, et al: Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 92: 275-280, 2012.
12. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
13. Lin CH, Yeh KT, Chang YS, Hsu N and Chang JG: Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. J Biomed Sci 17: 37, 2010.
14. Dufort S, Richard M-J, Lantuejoul S and de Fraipont F: Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 30: 57, 2011.
15. Ellison G, Donald E, McWalter G, et al: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 29: 132-139, 2010.
16. Goto K, Satouchi M, Ishii G, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23: 2914-2919, 2012.
17. Ellison G, Zhu G, Moulis A, Dearden S, Speake G and McCormack R: EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66: 79-89, 2013.
18. Denis MG, Theoleyre S, Chaplais C, et al: Efficient detection of EGFR alterations in lung adenocarcinomas. ASCO Meeting abstracts 28: 10556, 2010.
19. Sun P-L, Seol H, Lee HJ, et al: High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7: 323-330, 2012.
20. Leary AF, Castro DGd, Nicholson AG, et al: Establishing an EGFR mutation screening service for non-small cell lung cancer-sample quality criteria and candidate histological predictors. Eur J Cancer 48: 61-67, 2012.
21. Castro AS, Parente B, Goncalves I, et al: Epidermal growth factor recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Rev Port Pneumol 19: 7-12, 2013.
22. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
23. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
24. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
25. Matsuo K, Ito H, Yatabe Y, et al: Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 98: 96-101, 2007.
26. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
27. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
28. Yatabe Y, Kosaka T, Takahashi T and Mitsudomi T: EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29: 633-639, 2005.
29. Yatabe Y and Mitsudomi T: Epidermal growth factor receptor mutations in lung cancers. Pathol Int 57: 233-244, 2007.
30. Ueno T, Toyooka S, Suda K, et al: Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer 78: 207-211, 2012.
31. Choi YH, Lee JK, Kang HJ, et al: Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol 5: 1949-1952, 2010.
32. Girard N, Sima CS, Jackman DM, et al: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 39: 366-372, 2012.
33. Warth A, Penzel R, Brandt R, et al: Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 460: 407-414, 2012.
34. Zhou Q, Zhang X-C, Chen Z-H, et al: Relative abundance of EGFR mutations predicts benefit from Gefitinib treatment for advanced non small-cell lung cancer. J Clin Oncol 29: 3316-3321, 2011.